Literature DB >> 24925917

Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis.

Mona Bafadhel1, Lisa Davies2, Peter M A Calverley3, Shawn D Aaron4, Christopher E Brightling5, Ian D Pavord6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24925917     DOI： 10.1183/09031936.00062614

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  49 in total

1.  Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease.

Authors:  Jeong H Yun; Andrew Lamb; Robert Chase; Dave Singh; Margaret M Parker; Aabida Saferali; Jørgen Vestbo; Ruth Tal-Singer; Peter J Castaldi; Edwin K Silverman; Craig P Hersh
Journal:  J Allergy Clin Immunol       Date:  2018-04-28       Impact factor: 10.793

2.  Clinical value of IL-13 and ECP in the serum and sputum of eosinophilic AECOPD patients.

Authors:  Ting Li; Li Gao; Hong-Xia Ma; Yang-Yang Wei; Yue-Hua Liu; Ke-Ru Qin; Wen-Tao Wang; Hai-Long Wang; Min Pang
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-03

3.  Blood biomarkers as predictors of long-term mortality in COPD.

Authors:  Angelico Mendy; Erick Forno; Theophile Niyonsenga; Janvier Gasana
Journal:  Clin Respir J       Date:  2018-01-05       Impact factor: 2.570

Review 4.  Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.

Authors:  Prescott G Woodruff; Alvar Agusti; Nicolas Roche; Dave Singh; Fernando J Martinez
Journal:  Lancet       Date:  2015-05-02       Impact factor: 79.321

5.  Anti-IL-5 therapies for chronic obstructive pulmonary disease.

Authors:  Tim Donovan; Stephen J Milan; Ran Wang; Emma Banchoff; Patrick Bradley; Iain Crossingham
Journal:  Cochrane Database Syst Rev       Date:  2020-12-08

6.  A Revised Treatment Approach for Hospitalized Patients with Eosinophilic and Neutrophilic Exacerbations of Chronic Obstructive Pulmonary Disease.

Authors:  Emine Aksoy; Sinem Güngör; Meltem Çoban Ağca; İpek Özmen; Dildar Duman; Nagihan Durmuş Koçak; Ülkü Aka Aktürk; Eylem Tunçay; Cüneyt Saltürk; Murat Yalçınsoy; Birsen Ocaklı; Zuhal Karakurt
Journal:  Turk Thorac J       Date:  2018-09-13

Review 7.  From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.

Authors:  Ian D Pavord; Elisabeth H Bel; Arnaud Bourdin; Robert Chan; Joseph K Han; Oliver N Keene; Mark C Liu; Neil Martin; Alberto Papi; Florence Roufosse; Jonathan Steinfeld; Michael E Wechsler; Steven W Yancey
Journal:  Allergy       Date:  2021-09-16       Impact factor: 14.710

8.  Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.

Authors:  Christopher E Brightling; Eugene R Bleecker; Reynold A Panettieri; Mona Bafadhel; Dewei She; Christine K Ward; Xiao Xu; Claire Birrell; René van der Merwe
Journal:  Lancet Respir Med       Date:  2014-09-07       Impact factor: 30.700

9.  Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials.

Authors:  Pradeesh Sivapalan; Jonas Rutishauser; Philipp Schüetz; Jens-Ulrik Jensen; Charlotte Suppli Ulrik; Jörg D Leuppi; Lars Pedersen; Beat Mueller; Josefin Eklöf; Tor Biering-Sørensen; Vibeke Gottlieb; Karin Armbruster; Julie Janner; Mia Moberg; Therese S Lapperre; Thyge L Nielsen; Andrea Browatzki; Alexander Mathioudakis; Jørgen Vestbo
Journal:  Respir Res       Date:  2021-05-21

10.  Long-term oxygen treatment need is less frequent in eosinophilic COPD patients.

Authors:  Nilüfer Aylin Acet-Öztürk; Asli G Dilektasli; Özge Aydın-Güçlü; Ezgi Demirdöğen; Funda Coşkun; Ahmet Ursavaş; Mehmet Karadağ; Esra Uzaslan
Journal:  Clin Respir J       Date:  2021-10-26       Impact factor: 1.761
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.